Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells

Department of Immunology and Molecular Pathology, University College London, Hampstead Campus, Royal Free Hospital, London, United Kingdom.
The Journal of Immunology (Impact Factor: 5.36). 12/2007; 179(9):5803-10. DOI: 10.4049/jimmunol.179.9.5803
Source: PubMed

ABSTRACT We have previously described the functional activity of a human TCR specific for an HLA-A2-presented peptide derived from the Wilms tumor Ag 1 (WT1). Recent studies showed that the expression and function of human TCR was improved by the introduction of an additional disulfide bond between the alpha- and beta-chains or by the exchange of the human constant region for murine sequences. In this study, we analyzed the functional activity of WT1-TCR variants expressed in Jurkat cells and in primary T cells. The introduction of cysteine residues or murine constant sequences into the WT1-TCR did not result in a global reduction of mispairing with wild-type TCR chains. Instead, the level of mispairing was affected by the variable region sequences of the wild-type TCR chains. The analysis of freshly transduced peripheral blood T cells showed that the transfer of modified TCR constructs generated a higher frequency of Ag-responsive T cells than the transfer of the wild-type TCR. After several rounds of peptide stimulation this difference was no longer observed, as all transduced T cell populations accumulated approximately 90% of Ag-responsive T cells. Although the Ag-responsive T cells expressing the modified TCR bound the HLA-A2/WT1 tetramer more efficiently than T cells expressing the wild-type TCR, this did not improve the avidity of transduced T cells nor did it result in a measurable enhancement in IFN-gamma production and cytotoxic activity. This indicated that the enhanced tetramer binding of modified WT1-TCR variants was not associated with improved WT1-specific T cell function.

Download full-text


Available from: Reno Debets, Jul 29, 2015
  • Source
    • "Down-modulation of the WT1 T-cell receptor (TCR) is associated with a central memory phenotype, and high-affinity TCR mediates faster TCR down-regulation. The WT1-specific T cells proliferate and produce IFNγ and interleukin (IL)-2 in response to WT1 [6]. The authors concluded that the APCs need to express greater than 200 WT1 antigens to achieve TCR triggering and subsequent Tcell activation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The Second International Conference on Immunotherapy in Pediatric Oncology was held in Houston, Texas, USA, October 11-12, 2010, to discuss the progress and challenges that have occurred in cutting edge immunotherapeutic strategies currently being developed for pediatric oncology. Major topics included immune targeting of acute lymphoblastic leukemia and pediatric solid tumors, chimeric antigen receptors (CARs) for hematologic malignancies and solid tumors, enhancing graft-versus-leukemia for pediatric cancers, overcoming hurdles of immunotherapy, strategies to active the innate immune system, and moving immunotherapy beyond phase I studies. Significant progress has been made in the last 2 years both in the development of novel immunobiologics such as CARs, and in establishing survival benefits of an anti-GD2 monoclonal antibody in randomized studies. Although there is much excitement going forward, a great deal of laboratory and regulatory challenges lie ahead in improving the efficacy of each of these modalities as well as getting them to patients in a timely and cost-effective fashion. The resulting discussions will hopefully lead to new collaborations and insight for further translational and clinical studies.
    Pediatric Hematology and Oncology 09/2011; 28(6):459-60. DOI:10.3109/08880018.2011.596615 · 0.96 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Genetic modification of T cells with genes encoding a tumor-specific T-cell Receptor (TCR) represents a novel strategy to obtain large quantities of tumor-reactive T lymphocytes to be employed in adoptive cell therapy protocols. As a transfer method, lentiviral vectors might represent an appealing alternative to the most widely used oncoretroviral vectors, because they do not require cell division for nuclear uptake. We have characterized the TCR of a highly cytotoxic T lymphocyte (CTL) clone recognizing the HLA-A2-restricted Melan-A/MART-1 melanocyte differentiation antigen on both pulsed T2 cells and SK-23 MEL melanoma tumor cells. The ? (V?2.2) e ? (V?14) chains of the TCR were cloned and used to construct a lentiviral vector carrying a bidirectional promoter and capable of a robust and coordinated expression of the two transgenes. Transduction of Jurkat T leukemia cells showed that more than 60% of cells could be transduced without selection at a low MOI, as assessed by antigen-specific tetramer staining. High expression Jurkat clones disclosed that the new assembled TCR was at high intensity, very stable over time, and fully functional, as demonstrated by intracellular signaling upon TCR triggering. Transduction of activated PBMC produced a highly expressed transgenic TCR in around 5-10% of cells. This initial low, but clearly detectable, fraction of transduced lymphocytes could be quickly expanded (4-6 weeks) upon subsequent antigen-specific in vitro restimulation. The resulting population had a 50-70% of transgenic TCR expression and mainly a CD8+ phenotype, specifically recognized antigen-expressing melanoma cells (cytokine production and cytotoxic activity), and exerted relevant therapeutic effects in vitro upon adoptive transfer in SK-23 MEL-bearing mice. Our results indicate that LV constitute a valid tool for stable and high-intensity expression of transgenic TCR, and support further studies to address potential feasibility of this approach for clinical application.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Haematologica 2009 [Epub ahead of print] doi:10.3324/haematol.2009.006486 Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. This paper will now undergo editing, proof correction and final approval by the authors. Please note that during this production process changes may be made, and errors may be identified and corrected. The final version of the manuscript will appear both in the print and the online journal. All legal disclaimers that apply to the journal also pertain to this production process. Haematologica (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435, publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by the Ferrata Storti Foundation, a non-profit organiza-tion, and serves the scientific community with strict adherence to the principles of open access publishing ( In addition, the journal makes every paper published immediately available in PubMed Central (PMC), the US National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature. Haematologica is the official organ of the European Hematology Association (
Show more